Clinical Trial

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
Protocol Amendment History 1 change
notable Trial sites expanded: 46 -> 49 locations 2026-08-08
Trial Details
NCT Number NCT06767683
Lead Sponsor Alkermes, Inc.
Conditions Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Enrollment 256 participants
Start Date 2025-01-27
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-07